---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049046"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:30:12.863050+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Eledon Pharmaceuticals adopts updated director and officer indemnification agreement

## Summary
- Board approved new form of indemnification agreement for all directors and officers.
- Agreement provides indemnification to the maximum extent permitted by Delaware law.
- New agreement replaces existing indemnification agreements in place with directors and executive officers.
- No departures, elections, or appointments of officers were announced.
- Indemnification rights are in addition to any rights under certificate of incorporation or bylaws.

## SEC filing metadata
- accession: 0000950170-23-049046
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023049046/0000950170-23-049046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023049046/eldn-20230920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049046
- JSON: https://secwatch.observer/filing/0000950170-23-049046.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.